Research Peptide Quality Checklist: Verify CoA Authenticity

When a procurement officer asks how to verify a peptide CoA is authentic, the honest answer is that most published checklists stop at "check the lot number and the HPLC trace." That advice fails against the counterfeit CoAs we see in real laboratory intake. This research peptide quality checklist is built from actual failure cases our QA team has reviewed and from the internal re-verification workflow we run before any lot ships to an institutional buyer.

Why standard CoA checks miss counterfeit documents

A certificate of analysis is a document, and documents are cheap to fabricate. In the past 18 months, our QA group has reviewed third-party CoAs submitted by client labs for comparison against our own lots. Three recurring failure patterns appeared:

• Recycled chromatograms. The same HPLC trace image appeared across two different peptide sequences and two different lot numbers. Peak retention times were identical to the second decimal — physically implausible for distinct columns and mobile phases.
• Mass spec with no method metadata. An ESI-MS spectrum was pasted without instrument model, ionization mode, or calibration reference. The observed mass matched the theoretical monoisotopic mass to four decimals, which is a red flag rather than a green one; real spectra carry baseline noise and adduct peaks.
• Lot numbering that breaks internal logic. A supplier issued lot numbers that incremented by exactly one across a six-month span, with no batch gaps, no failed lots, and no rework codes. No GMP-adjacent manufacturer has that clean a production history.

None of these would be caught by a buyer who only confirms that a CoA exists and that the purity figure reads 98%.

The research peptide quality checklist: seven verification steps

1. Confirm the document is lot-specific, not product-specific

A genuine CoA is issued per lot. If the document lists a product code but no unique lot identifier, or if the lot identifier is reused across multiple order dates, handle the document as unverified. Ask the supplier to confirm the lot number printed on the vial label matches the CoA exactly, including any suffix codes.

2. Cross-check the analytical method against the claimed purity

Purity percentage is meaningless without the method. A CoA claiming 99.2% purity by HPLC should state column type, dimensions, particle size, mobile phase composition, gradient, flow rate, detection wavelength, and injection volume. If the method section is absent, the purity figure cannot be independently evaluated. For a deeper walkthrough of how we structure this section, see our Tirzepatide CoA guide.

3. Verify the mass spectrometry data is internally consistent

Check that the reported observed mass, theoretical mass, and calculated deviation are arithmetically consistent. Then check that the spectrum shows expected isotope envelope and adduct patterns. A clean single peak with no sodium or potassium adducts is unusual for real ESI data and often indicates a rendered or synthetic figure.

4. Look for the peptide content versus purity distinction

Purity (chromatographic) and peptide content (mass balance, often by elemental analysis or nitrogen determination) are different measurements. Counterfeit CoAs frequently report only purity and omit content, because content requires additional analytical work. For research applications where molar concentration matters, content data is not optional.

5. Check counter-ion and residual solvent disclosures

Trifluoroacetate (TFA) content, residual solvents, and water content affect the actual mass of peptide in a vial. A CoA that reports 98% purity but omits counter-ion data leaves the buyer unable to calculate accurate molarity. This is one of the most common omissions we see in submitted competitor documents.

6. Validate the issuing laboratory

Ask which laboratory performed the analysis and whether it is in-house or contracted. Request the laboratory's name and, where applicable, its accreditation scope. A CoA with no identifiable testing laboratory is an unsigned document. Our internal review requires that every lot trace back to a named analytical source with a dated raw data file.

7. Request the raw data file, not just the summary

This is the step most buyers skip. The summary CoA is a derived document. The raw chromatogram file (for example, a .raw or .cdx export) contains acquisition timestamps, instrument serial numbers, and method logs that are difficult to fabricate consistently. If a supplier cannot produce raw data on request, the CoA should be handled as unverified for procurement purposes.

What our internal re-verification workflow actually looks like

Before a lot is released, our QA team runs a three-stage review. Stage one is document completeness against a 14-point template. Stage two is analytical re-check: we re-run HPLC on a retained sample and compare retention time and peak area against the original data. Stage three is a raw data audit, where the reviewer opens the original acquisition file and confirms the method parameters match the CoA summary.

In a recent quarter, this workflow flagged two incoming reference materials where the supplied CoA reported 97.8% purity but our re-run returned 91.4% with an additional impurity peak at 8.2 minutes. The discrepancy was traced to a different gradient method being used by the supplier. The lot was rejected. That is the kind of gap a document-only check would have missed.

For buyers comparing GLP-1 research materials specifically, our Tirzepatide CoA walkthrough article breaks down the exact fields we require on every certificate, including the ones most suppliers leave blank.

Cost structure: why counterfeit CoAs persist

Full analytical characterization — HPLC, ESI-MS, peptide content, counter-ion, residual solvents, and water content — carries a real cost per lot. When buyers pressure suppliers on unit price alone, the analytical budget is the first thing cut. Counterfeit CoAs exist because a document costs almost nothing to produce, while a genuine multi-method analysis does not. Institutional buyers who specify the analytical panel in the purchase contract, rather than accepting whatever CoA arrives, close that gap.

Red-flag summary for procurement teams

• Purity figure with no method description
• Identical chromatogram images across different lots or sequences
• Mass spec with no instrument or method metadata
• No peptide content, counter-ion, or residual solvent data
• No named testing laboratory
• Refusal or delay when raw data is requested
• Lot numbering with no gaps, rework codes, or failed batches

Any single red flag warrants a request for raw data. Two or more should pause the order until the supplier can reconcile the discrepancy in writing.

Conclusion: make the research peptide quality checklist part of the contract

A research peptide quality checklist is only useful if it is applied before payment, not after delivery. Write the analytical requirements into the purchase order: named laboratory, method parameters, raw data on request, and lot-specific documentation. That converts the checklist from a suggestion into an enforceable specification.

If your laboratory needs to verify a CoA against a specific lot, or you want to review our standard analytical panel before ordering, talk to our QA team and request a quote with the documentation package included.